4.7 Review

Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research

Journal

FRONTIERS IN ENDOCRINOLOGY
Volume 11, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2020.576632

Keywords

genome editing; beta cell; genome-wide association studies; maturity onset of diabetes of the young; stem cells; mouse models

Funding

  1. Wellcome Trust [WT098424AIA, 212625/Z/18/Z]
  2. MRC Programme [MR/R022259/1, MR/J0003042/1, MR/L020149/1]
  3. Experimental Challenge Grant (DIVA) [MR/L02036X/1]
  4. MRC [MR/N00275X/1]
  5. Diabetes UK [BDA/11/0004210, BDA/15/0005275, BDA 16/0005485]
  6. Imperial Confidence in Concept (ICiC)
  7. Royal Society Wolfson Research Merit Award
  8. European Union's Horizon 2020 research and innovation programme via the Innovative Medicines Initiative 2 Joint Undertaking [115881]
  9. European Union
  10. EFPIA
  11. BBSRC [BB/J015873/1] Funding Source: UKRI
  12. MRC [MR/R010676/1, MR/M012646/1, MR/L020149/1, MR/L02036X/1, MR/R022259/1, MR/N00275X/1, MR/K001981/1, MR/N020472/1] Funding Source: UKRI
  13. Medical Research Council [MR/N00275X/1] Funding Source: researchfish

Ask authors/readers for more resources

The inheritance of variants that lead to coding changes in, or the mis-expression of, genes critical to pancreatic beta cell function can lead to alterations in insulin secretion and increase the risk of both type 1 and type 2 diabetes. Recently developed clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) gene editing tools provide a powerful means of understanding the impact of identified variants on cell function, growth, and survival and might ultimately provide a means, most likely after the transplantation of genetically corrected cells, of treating the disease. Here, we review some of the disease-associated genes and variants whose roles have been probed up to now. Next, we survey recent exciting developments in CRISPR/Cas9 technology and their possible exploitation for beta cell functional genomics. Finally, we will provide a perspective as to how CRISPR/Cas9 technology may find clinical application in patients with diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available